# Cancer associated variant enrichment CAVE, a gene agnostic approach to identify low burden variants in chronic lymphocytic leukemia

**Authors:** Adar Yaacov, Gregory Lazarian, Tatjana Pandzic, Simone Weström, Panagiotis Baliakas, Samia Imache, Valérie Lefebvre, Florence Cymbalista, Fanny Baran-Marszak, Shai Rosenberg, Thierry Soussi

PMC · DOI: 10.1038/s41598-024-73027-1 · Scientific Reports · 2024-09-20

## TL;DR

CAVE is a new tool that helps detect low-level genetic changes in cancer cells, which can be important for treatment decisions.

## Contribution

CAVE introduces a gene-agnostic method to identify low-burden cancer driver variants in NGS data.

## Key findings

- CAVE can detect low-burden variants starting at variant allele frequencies as low as 0.3%.
- In silico and orthogonal validation confirmed the accuracy of CAVE in identifying true driver variants.
- CAVE is applicable to any cancer-related NGS workflow for detecting clinically relevant low-burden variants.

## Abstract

Intratumoral heterogeneity is an important clinical challenge because low burden clones expressing specific genetic alterations drive therapeutic resistance mechanisms. We have developed CAVE (cancer-associated variant enrichment), a gene-agnostic computational tool to identify specific enrichment of low-burden cancer driver variants in next-generation sequencing (NGS) data. For this study, CAVE was applied to TP53 in chronic lymphocytic leukemia (CLL) as a cancer model. Indeed, as TP53 mutations are part of treatment decision-making algorithms and low-burden variants are frequent, there is a need to distinguish true variants from background noise. Recommendations have been published for reliable calling of low-VAF variants of TP53 in CLL and the assessment of the background noise for each platform is essential for the quality of the testing. CAVE is able to detect specific enrichment of low-burden variants starting at variant allele frequencies (VAFs) as low as 0.3%. In silico TP53 dependent and independent analyses confirmed the true driver nature of all these variants. Orthogonal validation using either ddPCR or NGS analyses of follow-up samples confirmed variant identification. CAVE can be easily deployed in any cancer-related NGS workflow to detect the enrichment of low-burden variants of clinical interest.

The online version contains supplementary material available at 10.1038/s41598-024-73027-1.

## Linked entities

- **Genes:** TP53 (tumor protein p53) [NCBI Gene 7157]
- **Diseases:** chronic lymphocytic leukemia (MONDO:0004948), CLL (MONDO:0004948)

## Full-text entities

- **Genes:** TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}
- **Diseases:** Cancer (MESH:D009369), CLL (MESH:D015451)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11415367/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11415367/full.md

## References

4 references — full list in the complete paper: https://tomesphere.com/paper/PMC11415367/full.md

---
Source: https://tomesphere.com/paper/PMC11415367